Claris Lifesciences Limited (Claris) was the Holding Company of Claris Injectables Limited, a wholly-owned subsidiary dealing in Specialty Injectables business that was carved out in Nov 2014. Claris Injectables was sold to Baxter International Inc. in Jul 2017.

Since its inception in 1999, Claris worked towards creating a niche in a highly-regulated business. Over a history of 17 years, we created nearly a billion-dollar valuation, with establishing world-class integrated business model that helped garner several stringent international regulatory approvals, including US FDA.

Claris also entered a Joint Venture (JV) in August 2013 with Japanese companies Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. Ltd. for its Infusion business in India & emerging markets, selling 80% stake and creating JV company ‘Claris Otsuka Private Limited’ (COPL). Claris has completed the sale of its remaining stake to Otsuka, and exited from the JV.

Claris’ growth is escalated through the diligent work carried out by members to take the organisation to newer heights year-on-year. This proficiency was reconfirmed through consecutive 8 wins as one of ‘India’s Best Companies To Work For’ and one of the best companies in ‘Healthcare’ industry by The Economic Times and Great Place to Work® Institute, India.

Parallel to striving for excellence, Claris serves as a socially responsible organisation, fulfilling goals beyond the business commitments. Hence, we always support various social causes aimed at promoting sports, health, education, and culture encompassing the broader spectrum of society.

Claris is now a financial management company, with interests in investing in new businesses with specialty pharmaceuticals and FMCG as focus. With the determined notion to prosper in all endeavours we undertake, we will always make every effort to grab an opportunity to take the organisation to the next growth trajectory.


Content provided by Claris Lifesciences, Info Edge India Limited disclaims all warranties against infringement.
Visit Security Guidelines and Terms and conditions for more comprehensive information in this regard.